T6650 |
Sabutoclax
|
1228108-65-3
|
98%
|
|
Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
|
T12907 |
SIAIS178
|
2376047-73-1
|
98%
|
|
SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM).
|
T28374 |
PF-06651481-00
|
1391063-17-4
|
98%
|
|
PF-06651481-00 is a Bosutinib analog and a Bcr-Abl inhibitor.
|
T10583 |
Bosutinib D8
|
T10583
|
98%
|
|
Bosutinib D8 is a deuterium-labeled Bosutinib. Bosutinib (SKI-606) is a dual Src/Abl inhibitor (IC50s: 1.2 nM/1 nM).
|
T22378 |
Nilotinib hydrochloride
|
923288-95-3
|
98%
|
|
Nilotinib hydrochloride, the hydrochloride salt form of nilotinib, is an orally bioavailable Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
|
T14925 |
Cenisertib
|
871357-89-0
|
98%
|
|
Cenisertib (AS-703569) is a multi-kinase inhibitor and blocks the activity of Aurora-kinase-A/B, AKT, ABL1, STAT5, and FLT3. Cenisertib inhibits tumor growth in ...
|
T10488 |
BCR-ABL-IN-1
|
188260-50-6
|
98%
|
|
BCR-ABL-IN-1 is a BCR-ABL tyrosine kinase inhibitor (pIC50: 6.46) and may be used in the research of chronic myelogenous leukemia.
|
T34656 |
SKLB 1028
|
1350544-93-2
|
98%
|
|
SKLB1028 is a new type of oral multikinase inhibitor of EGFR, FLT3, and Abl. It shows excellent activity in FLT3-driven AML models and considerable potency in CM...
|
T16545 |
Pivanex
|
122110-53-6
|
98%
|
|
Pivanex is a derivative of Butyric acid and is an orally active HDAC inhibitor. Pivanex has antimetastic and antiangiogenic properties. Pivanex down-regulates bc...
|
T11961 |
MBM-55S
|
2083624-07-9
|
98%
|
|
MBM-55S is an effective inhibitor of Nek2 with an IC50 of 1 nM. MBM-55S indecus cell cycle arrest and apoptosis thereby inhibiting the proliferation of cancer ce...
|
T22303 |
Dasatinib hydrochloride
|
854001-07-3
|
98%
|
|
Dasatinib hydrochloride is a highly ATP competitive, potent, orally active inhibitor of dual Src/Bcr-Abl(with Ki values of 16 pM and 30 pM for Src and Bcr-Abl, r...
|
T7186 |
CZC-8004
|
916603-07-1
|
|
|
CZC-8004 is a pan-kinase(ABL kinase) inhibitor and binds a range of tyrosine kinases.
|
T21785 |
AG957
|
140674-76-6
|
|
|
Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in ch...
|
T11641 |
N-Desmethyl imatinib
|
404844-02-6
|
|
|
N-Desmethyl imatinib is a metabolite of Imatinib, which is a multi-target inhibitor of c-Kit, v-Abl, and PDGFR.
|
T4618 |
BGG463
|
890129-26-7
|
100%
|
|
BGG463 can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with a 50% inhibitory concentration (IC50) of 0.25 μM, 0.09 μM and 0.590 μM, respectively.
|
T16750 |
Rigosertib
|
592542-59-1
|
97.33%
|
|
Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer agent, which...
|
T6348 |
NVP-BHG712
|
940310-85-0
|
97.96%
|
|
NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c...
|
T4191 |
Multi-kinase inhibitor 1
|
778274-97-8
|
98%
|
|
Multi-kinase inhibitor I is a Multi-kinase inhibitor.
|
T2116 |
AEE788
|
497839-62-0
|
98%
|
|
AEE788 has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.
|
T30855 |
CGP77675
|
234772-64-6
|
98.23%
|
|
CGP77675 is a potent and selective inhibitor of Src family kinase with IC50s of 5-20 and 40 nM for the phosphorylation of peptide substrates and autophosphorylat...
|